- Trial phase
- Approved
- Time to market
- Already approved and marketed (since October 2020). Maftivimab monotherapy for BDBV is at the preclinical/investigational stage with no defined timeline.
- Why 4/10
- No hard, dated binary catalyst (PDUFA, pivotal readout, or AdComm) is scheduled in the next ~12 months. INMAZEB was approved in 2020; the next potential catalyst would be clinical trial data from WHO-recommended maftivimab monotherapy studies for Bundibugyo ebolavirus, but no trial start or readout date has been announced.
INMAZEB is already approved and commercialized with no upcoming PDUFA or pivotal readout. The BARDA extension (~$270M through 2031) provides predictable, modest government revenue. The WHO-backed maftivimab monotherapy trials for Bundibugyo ebolavirus are an early-stage, non-binary catalyst, clinical data from those trials (if initiated) would be the next meaningful event, but no timeline has been announced. For a company of Regeneron's scale, INMAZEB is a negligible financial driver.
Price Chart
Executive Summary
Maftivimab is one of three monoclonal antibodies in Regeneron's fixed-dose combination INMAZEB (atoltivimab/maftivimab/odesivimab-ebgn), the first FDA-approved treatment for Ebola (Zaire ebolavirus), approved in October 2020. INMAZEB is a marketed product with government stockpile contracts but is a very small revenue contributor within Regeneron's $14B+ annual portfolio dominated by Dupixent, EYLEA HD, and Libtayo. The drug has no pending regulatory binary catalyst. Recent developments include a WHO recommendation (May 2026) to evaluate maftivimab as a monotherapy in clinical trials for the Bundibugyo ebolavirus outbreak, and a BARDA contract extension (Oct 26, 2026) worth ~$270M through 2031 for U.S. government supply.
How It Works
Maftivimab is a lab-made antibody (a monoclonal antibody) that sticks to the outer surface protein (glycoprotein) of the Ebola virus. By binding to the virus, it stops the virus from entering human cells and also flags the virus for destruction by the immune system. It is one of three such antibodies in the INMAZEB cocktail, each binding to a different spot on the virus to maximize coverage.
Trial Status
INMAZEB (atoltivimab/maftivimab/odesivimab) was FDA-approved on October 14, 2020 for treatment of Zaire ebolavirus, based on the Phase 2/3 PALM trial. It is commercially available and supplied to U.S. and allied government stockpiles. Maftivimab as a monotherapy is being evaluated preclinically for Bundibugyo ebolavirus (BDBV) following a May 2026 WHO recommendation, with a non-human primate efficacy preprint published in October 2026.
The Two-Sided Case
Upcoming Catalysts
- WHO-recommended clinical trials of maftivimab monotherapy for Bundibugyo ebolavirus, no start date announced
- BARDA contract deliveries through 2031 (~$270M total), ongoing, not a binary event
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Regeneron Pharmaceuticals, Inc. Press Release REGN ·Originating report